According to Yuen et al. and Schalper et al., high systemic and tumor-associated IL-8 levels that correlate with the reduced benefit of anti-PD-L1 therapies and can reverse the impacts of IL-8-mediated myeloid inflammation will be essential for improving outcomes of patients treated with immune checkpoint inhibitors [47,48]. This evidence concerns the gene CXCL8 and neoplasm.